TFF Pharmaceutical’s Thin Film Freezing technology platform has broad applicability to convert drugs (small and large molecules) and vaccines into a dry powder formulation for local administration
Aptar Pharma has announced a collaboration with TFF Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing and commercialising innovative drug products based on its patented Thin Film Freezing technology platform.
The collaboration is aimed at developing and testing the administration of dry powder vaccines utilising TFF Pharmaceutical’s Thin Film Freezing technology and Aptar Pharma’s proprietary intranasal Unidose (UDS) Powder Nasal Spray System.
A need for alternative routes of vaccination, such as intranasal, was highlighted at the White House Summit on the Future of COVID-19 Vaccines, which took place in July 2022. The development of an effective intranasal vaccine has numerous potential advantages over conventional, subcutaneous or intramuscular-based delivery. First, the nasal passageway is very often the first point of entry for certain pathogens; if the pathogen can be halted in the nasal passages, curtailing the spread of infection further, this could lead to an improved overall prognosis. In addition, the direct immunisation of nasal mucosa may promote systemic and mucosal immunity, which may help prevent viral shedding and disease transmission.
Furthermore, self-administration of a nasal powder vaccine provides for “needle free” administration to the patient avoids the need for syringe disposal, and potentially simplifies global distribution with the elimination of extreme cold from the supply chain. These aspects of nasal delivery could open up vaccine availability to larger populations in regions and countries with limited refrigeration infrastructure.
Intranasal dry powder vaccines could be a true game changer for people around the world
During the Vaccines Summit-2022, which took place from October 11 to 13, 2022, in Washington, DC, Aptar Pharma presented research findings from their collaboration with TFF Pharmaceuticals. The presentation highlighted data related to nasal deposition of a dry powder vaccine, physical characteristics of the administered formulation, the integrity and activity testing of the dry powder vaccine after administration, and the emitted particle size. The amount of dry powder delivered to the targeted region of the nasal cavity was also presented. Aptar Pharma will present additional data on these efforts at the World Vaccine & Immunotherapy Congress, which will be held in San Diego, CA, from November 28 to December 1, 2022.
“We are very excited to partner with Aptar Pharma to test our Thin Film Freezing formulation with their unique intranasal device,” said Glenn Mattes, President & CEO of TFF Pharmaceuticals. “By combining our collective and proprietary expertise in drug development, device engineering and formulation technologies, we believe this collaboration has the potential to create ground-breaking advancements in the field of drug delivery. Intranasal dry powder vaccines could be a true game changer for people around the world.”
“The nasal vaccine formulation developed using TFF Pharmaceutical’s technology combines the antigen and adjuvant into one ready-to-use device,” commented Dr Julie D. Suman, Vice President, Scientific Affairs at Aptar Pharma. “This eliminates the need for combining separate vials, which potentially saves time, reduces human error and medical waste.”
The results of the feasibility testing will be published by Aptar Pharma, The University of Texas at Austin (UT) and TFF Pharmaceuticals in the coming months. Aptar, UT and TFF have summarised the results of the initial intranasal vaccine feasibility testing in a pre-print publication, to be followed by a peer-reviewed publication in the coming months.